Stockwatch: Salutary lessons in drug commercialization
This article was originally published in Scrip
Executive Summary
Last week, personalized cancer vaccine company Dendreon appeared to be in terminal decline as it struggles with low sales of its expensive product for prostate cancer, Provenge (sipuleucel-T), in the face of cheaper, more easily administered and more efficacious competition, and also with a large debt mountain. Dendreon is a rare and, you would think, salutary event in life science investing.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.